11 October 2019 - Public comment period extended through 8 November 2019; public meeting now to take place on 9 December 2019 in Oakland, CA.

The Institute for Clinical and Economic Review (ICER) today released an updated draft evidence report assessing the comparative clinical effectiveness and value of treatments for rheumatoid arthritis.

After initially publishing an earlier version of this draft evidence report on 26 September 2019, ICER’s internal reviewers identified the need to reevaluate some of the assumptions and calculations in the report to better align our economic modelling with how patients transition between these therapies in the real world. 

In our updated model, patients that are failed by first-line treatment now transition to a market basket of targeted immune modulators, instead of palliative care. Also, because clinical differentiation between these therapies is uncertain over time, we will now analyse their cost-effectiveness in the first year of use, instead of over a patient’s lifetime.

Read ICER Announcement